{"task_id": "cbe77debf4a470d4", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 86/464)", "text": "rin\nCLINICAL FEATURES (CONT\u2019D)\nGlomerulopathies\n71\n\n--- Page 93 ---\nSPECIFIC ENTITIES (CONT\u2019D)\n\u0002\nPROGNOSIS\n40% remission, 30% stable, 30% end\nstage renal disease over 10 20 years\nFOCAL SEGMENTAL GLOMERULOSCLEROSIS\n(FSGS) (more severe form of MCD)\n\u0002\nCAUSES\nprimary, secondary (Li, heroin, lympho\nmas, HIV. May also be associated with sickle cell\ndisease, hypertension, and obesity)\n\u0002\nCLINICAL\nFEATURES\npure\nnephrotic\n(minimal\nhematuria, no RBC casts)\n\u0002\nPATHOLOGY\nlight microscopy (segmental areas of\nsclerosis), immunofluorescence (no immune com\nplexes), electron microscopy (effacement of podo\ncyte foot processes)\n\u0002\nTREATMENTS\nsteroid, cyclophosphamide, cyclo\nsporin\n\u0002\nPROGNOSIS\nlarge\npercentage\nwith\nend stage\nrenal disease over 15 20 years\nMEMBRANOPROLIFERATIVE GN (MPGN)\n\u0002\nPATHOPHYSIOLOGY\ntype 1 = immune complex\ndeposition disease. Type 2 = activation of comple\nment system via C3 nephritic factor (IgG against C3\nconvertase), with decreased C3 and normal C4\n\u0002\nCAUSES\nprimary, secondary type 1 (HCV, HBV,\nendocarditis, abscess, infected shunts, CLL, lym\nphomas, SLE, cryoglobulinemia), secondary type\n2 (partial lipodystrophy, sickle cell, complement\ndeficiency)\n\u0002\nCLINICAL FEATURES\n50% nephrotic (usually type 1),\n20% asymptomatic proteinuria/hematuria, 30%\nacute nephritic (usually type 2)\n\u0002\nPATHOLOGY\nlight microscopy (basement mem\nbrane thickening, mesangial cell hypercellularity),\nimmunofluorescence (complements along capil\nlary walls), electron microscopy (type 1 shows dis\ncrete deposits in mesangium, type 2 shows depos\nits as continuous ribbon in glomerular basement\nmembrane)\n\u0002\nTREATMENTS\nsteroid, cyclophosphamide, cyclo\nsporin\n\u0002\nPROGNOSIS\n40 75% end stage renal disease over\n10 15 years\nRAPIDLY PROGRESSIVE GN (RPGN)\nANTI\nGLOMERULAR BASEMENT MEMBRANE ANTIBODY\nDISEASE\n\u0002\nPATHOPHYSIOLOGY\nantibody against a3 chain of\ntype IV collagen\n\u0002\nCAUSES\nGoodpasture\u2019s syndrome, anti GBM anti\nbody nephritis\n\u0002\nCLINICAL FEATURES\nnephritic (hematuria, protei\nnuria, ARF). Goodpasture syndrome also has lung\nSPECIFIC ENTITIES (CONT\u2019D)\ninvolvement whereas anti GBM antibody nephritis\naffects kidney alone\n\u0002\nPATHOLOGY\nimmunofluorescence (linear staining)\n\u0002\nTREATMENTS\nplasmapheresis with IV pulse ster\noids followed by PO steroids with PO cyclopho\nsphamide for 1 year\nRAPIDLY PROGRESSIVE GN (RPGN)\nIMMUNE\nCOMPLEX\n\u0002\nPATHOPHYSIOLOGY\ndeposition\nof\ncirculating\nimmune complex in glomeruli, usually in suben\ndothelial location\n\u0002\nCAUSES\nSLE, HBV, HCV, endocarditis, post strep\nGN, post infectious GN, IgA nephropathy, cryoglo\nbulinemia, shunt nephritis\n\u0002\nCLINICAL FEATURES\nnephritic (hematuria, protei\nnuria, ARF)\n\u0002\nPATHOLOGY\nimmunofluorescence\n(granular\nstaining)\n\u0002\nTREATMENTS\nIV pulse steroids followed by PO ster\noids with IV monthly cyclophosphamide for 1 year\nRAPIDLY PROGRESSIVE GN (RPGN)\nPAUCI\nIMMUNE COMPLEX\n\u0002\nCAUSES\nWegener\u2019s (c anca), microscopic polyan\ngiitis (p anca), Churg Strauss\n\u0002\nCLINICAL FEATURES\nnephritic (hematuria, protei\nnuria, ARF). May have lung involvement\n\u0002\nPATHOLOGY\nimmunofluorescence (no staining)\n\u0002\nTREATMENTS\nIV pulse steroids followed by PO\nsteroids with PO cyclophosphamide for 1 year\nIGA NEPHROPATHY\n\u0002\nPATHOPHYSIOLOGY\nabnormal regulation of produc\ntion or structure of IgA in response to environmental\nantigens ! illness triggers production of IgA and/or\nIgA immune complex ! deposit in mesangium\n\u0002\nCAUSES\nprimary, secondary (HSP, celiac disease,\ndermatitis herpetiformis, cirrhosis, HIV, malignan\ncies, seronegative spondyloarthropathies)\n\u0002\nCLINICAL\nFEATURES\n50% recurrent macroscopic\nhematuria with URTI, 30 40% persistent microhe\nmaturia and proteinuria, 10% rapidly progressive\nrenal failure, <10% nephrotic syndrome\n\u0002\nPATHOLOGY\nlight microscopy (focal or diffuse\nmesangial hypercellularity and matrix expansion),\nimmunofluorescence (extensive IgA deposition\nin mesangium and capillary walls), electron micro\nscopy (mesangial deposits). Patients presenting\nwith nephrotic syndrome may also have nephrotic\nhistologic picture. Note most of the time IgA\nnephropathy is a clinical diagnosis. No biopsy\nunless ARF or severe symptoms\n72\nGlomerulopathies", "text_length": 4080, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 86/464)", "type": "chunk", "chunk_index": 85, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.358014", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.359133", "status": "complete", "chunks_added": 3}